The ATP1A2 gene encodes the alpha-2 (α2) subunit of the Na⁺/K⁺-ATPase, a fundamental membrane enzyme that maintains the electrochemical gradients essential for cellular function. The Na⁺/K⁺-ATPase uses ATP to pump three sodium ions out of the cell and two potassium ions into the cell, creating gradients that are critical for neuronal excitability, secondary active transport, cell volume regulation, and resting membrane potential maintenance. While the alpha-1 subunit (ATP1A1) is ubiquitously expressed, the alpha-2 isoform (ATP1A2) shows a highly restricted expression pattern with particularly high levels in the brain, especially in astrocytes. This astrocyte-specific expression makes ATP1A2 uniquely important for astrocyte-neuron interactions, including potassium buffering, glutamate clearance, calcium signaling, and metabolic support of neurons. Mutations in ATP1A2 have been directly linked to familial hemiplegic migraine type 2 (FHM2), epilepsy, and more recently implicated in amyotrophic lateral sclerosis (ALS). The gene's dysfunction leads to impaired neuronal excitability, disrupted calcium homeostasis, and altered intracellular signaling, all of which are central features of neurodegenerative disease pathogenesis. Located on chromosome 1q21.3, ATP1A2 represents a critical node linking astrocyte function to neuronal survival in health and disease.
Allen Human Brain Atlas — ATP1A2 Expression: Highest expression in cortical regions, thalamus, and brainstem. Astrocyte-specific enrichment confirmed via single-cell RNA-seq datasets. Regional vulnerability patterns align with ATP1A2 dysfunction in migraine with aura and ALS. [](https://pubmed.ncbi.nlm.nih.gov/30851891/) [](https://pubmed.ncbi.nlm.nih.gov/31928954/)
| Attribute |
Value |
| Gene Symbol |
ATP1A2 |
| Full Name |
ATPase Na⁺/K⁺ Transporting Subunit Alpha 2 |
| Chromosome |
1q21.3 |
| NCBI Gene ID |
476 |
| OMIM |
182340 |
| Ensembl ID |
ENSG00000118520 |
| UniProt ID |
P13637 (also P24720 isoform) |
| Protein Size |
1018 amino acids |
| Gene Type |
Protein-coding |
The Na⁺/K⁺-ATPase is a P-type ATPase that belongs to a family of ion pumps that transport cations across cellular membranes using ATP hydrolysis. The enzyme is composed of multiple subunits:
- Alpha subunit (catalytic): The largest subunit (~1000 amino acids) that contains the ATP-binding site, ion binding sites, and performs the actual pumping cycle. Four isoforms exist (ATP1A1-ATP1A4), with different tissue distributions.
- Beta subunit: Required for proper membrane insertion and enzyme stability
- Gamma subunit (FXYD2): Modulates enzyme activity and regulates its affinity for sodium
¶ Structure and Mechanism
The alpha subunit contains:
- N-domain: ATP-binding region
- P-domain: Phosphorylation site (Asp369) during the transport cycle
- A-domain: Actuator domain that undergoes conformational changes
- Transmembrane domains: 10 transmembrane helices forming the ion channel
The enzyme cycles between two major conformational states (E1 and E2), undergoing phosphorylation and dephosphorylation to transport ions. This active transport creates:
- Intracellular Na⁺: ~10-15 mM (low compared to extracellular ~140 mM)
- Extracellular Na⁺: ~140 mM
- Intracellular K⁺: ~140 mM (high compared to extracellular ~3-5 mM)
- Resting membrane potential: Approximately -70 mV
¶ ATP1A2 Expression and Cell-Type Specificity
ATP1A2 exhibits a highly specific expression pattern that distinguishes it from other alpha subunit isoforms:
ATP1A2 is predominantly expressed in:
- Astrocytes: Highest expression in perivascular and perineuronal astrocytes
- Oligodendrocytes: Lower but significant expression
- Some neuronal populations: Certain cortical and hippocampal neurons
| Isoform |
Primary Expression |
Cellular Location |
| ATP1A1 |
Ubiquitous |
All cell types |
| ATP1A2 |
Brain (astrocytes) |
Astrocyte end-feet |
| ATP1A3 |
Brain (neurons) |
Neurons |
| ATP1A4 |
Testis |
Sperm |
High expression in:
Astrocytic ATP1A2 is concentrated at:
- Perivascular end-feet: Adjacent to blood vessels
- Perisynaptic processes: Surrounding synapses
- Gap junction coupling: Connexin-43 positive astrocyte networks
This specific localization enables ATP1A2 to function as a primary sensor of extracellular potassium and glutamate at synaptic interfaces.
One of the most critical functions of astrocytic ATP1A2 is potassium homeostasis:
- During neuronal activity, K⁺ is released into the extracellular space
- Astrocytes take up excess K⁺ through ATP1A2 and Kir4.1 channels
- K⁺ is redistributed through the astrocyte network via gap junctions
- This buffering prevents extracellular K⁺ accumulation that could disrupt neuronal excitability
ATP1A2 is particularly important for:
- Maintaining low extracellular K⁺ (~3 mM) during high neuronal activity
- Preventing spreading depolarization
- Supporting repeated neuronal firing
Astrocytes clear glutamate from the synaptic cleft via:
- EAAT1 (GLAST) and EAAT2 (GLT-1) glutamate transporters
- Na⁺ gradient driving glutamate uptake
- ATP1A2 maintains this Na⁺ gradient
When ATP1A2 is impaired:
- Glutamate clearance is compromised
- Excitotoxicity results from excessive glutamate
- This mechanism is particularly relevant in ALS and other excitotoxic diseases
Astrocytic ATP1A2 modulates intracellular calcium:
- Na⁺ gradient affects Na⁺/Ca²⁺ exchanger (NCX) function
- Altered Ca²⁺ signaling affects astrocyte-neuron communication
- Impaired Ca²⁺ dynamics reduce neuroprotective signaling
ATP1A2 supports astrocyte metabolic functions:
- Provides energy for glycogen breakdown
- Supports the astrocyte-neuron lactate shuttle
- Maintains ion homeostasis during active neurotransmission
ATP1A2 mutations are the primary cause of FHM2, a rare autosomal dominant migraine subtype with aura including temporary paralysis on one side of the body:
Pathogenic Mechanisms:
- Mutant ATP1A2 reduces Na⁺/K⁺ pump activity
- Impaired glutamate clearance leads to cortical spreading depression
- Reduced potassium buffering contributes to neuronal hyperexcitability
- Altered intracellular Na⁺ affects voltage-gated calcium channels
Mutations:
- Over 40 pathogenic mutations identified
- Most are missense mutations affecting ion binding or ATP hydrolysis
- Mutations have variable penetrance and severity
- Some mutations also cause epilepsy without migraine
Therapeutic Implications:
- Acetazolamide (carbonic anhydrase inhibitor) can be effective
- Potassium channel openers under investigation
- Gene therapy approaches being explored
ATP1A2 mutations are associated with various epilepsy syndromes:
- FHM2 with epilepsy: Up to 20% of FHM2 patients have seizures
- Dravet syndrome: Some patients have ATP1A2 mutations
- Rolandic epilepsy: Association with certain ATP1A2 variants
Mechanisms:
- Impaired astrocytic potassium buffering causes neuronal hyperexcitability
- Reduced glutamate clearance leads to excitotoxicity
- Altered Na⁺/Ca²⁺ exchange affects neuronal calcium homeostasis
Recent research has implicated ATP1A2 in ALS pathogenesis:
Evidence:
- Reduced ATP1A2 expression in ALS patient brain tissue and spinal cord
- ALS-associated mutations in ATP1A2 identified in some patients
- Astrocyte dysfunction is a key feature of ALS (non-cell autonomous toxicity)
- Impaired glutamate clearance is a hallmark of ALS astrocytes
Mechanisms:
- Loss of astrocytic ATP1A2 impairs glutamate uptake (via EAAT2)
- Reduced potassium buffering contributes to motor neuron excitotoxicity
- Altered astrocyte-neuron metabolic coupling
- Activated astrocytes release toxic factors
While ATP1A2 is not directly mutated in AD, its function is affected:
Observations:
- Reduced Na⁺/K⁺-ATPase activity in AD brain
- ATP1A2 expression decreased in hippocampus and cortex
- Impaired astrocyte function contributes to disease progression
Mechanisms:
- Amyloid-beta directly inhibits Na⁺/K⁺-ATPase
- Tau pathology affects pump localization to astrocyte processes
- Impaired astrocyte function worsens neuronal dysfunction
ATP1A2 dysfunction may contribute to PD through:
- Altered astrocyte function in the substantia nigra
- Impaired potassium buffering affecting dopaminergic neurons
- Possible interaction with alpha-synuclein pathology
Beyond ion transport, ATP1A2 serves as a signaling molecule:
ATP1A2 can activate Src family kinases:
- Binding of ouabain (a specific Na⁺/K⁺-ATPase ligand) at low concentrations triggers signaling
- Activation of EGFR transactivation
- Upregulation of antioxidant responses
- Anti-apoptotic signaling through PI3K/AKT pathway
ATP1A2 is sensitive to oxidative stress:
- Oxidative modifications reduce pump activity
- This creates a feedforward loop in neurodegeneration
- Antioxidants can partially protect ATP1A2 function
ATP1A2 interacts with:
- Ankyrin: Membrane cytoskeleton linkage
- Na⁺/Ca²⁺ exchanger (NCX): Coupled activity
- GLUT1 (SLC2A1): Glucose transporter coordination
- AQP4: Water channel at perivascular end-feet
Existing Therapeutics:
- Digoxin/Ouabain: Cardiotonic steroids that inhibit Na⁺/K⁺-ATPase at high doses; low-dose signaling effects being explored
- Acetazolamide: Carbonic anhydrase inhibitor, effective in some FHM2 patients
Under Investigation:
- ** isoform-selective activators**: Compounds that specifically activate ATP1A2
- Gene therapy: Viral vector-mediated ATP1A2 delivery to brain
- Protein replacement therapy: Recombinant ATP1A2 delivery
- Achieving sufficient brain penetration
- Balancing ion transport vs. signaling functions
- Cell-type specificity (targeting astrocytes specifically)
- Safety concerns (narrow therapeutic window for some compounds)
- Developmental expression: Increases after birth, peaks in adulthood
- Activity-dependent: Neuronal activity can regulate expression
- Hormonal regulation: Thyroid hormone affects expression
- Phosphorylation: Multiple sites regulate activity
- Glycosylation: N-linked glycosylation affects membrane targeting
- Palmitoylation: Affects membrane localization
- Reduced expression in AD, PD, ALS
- Reduced activity in ischemia
- Oxidative inhibition in aging
- ATP1A2 knockout: Neonatal lethality (respiratory failure)
- Conditional knockout: Astrocyte-specific deletion shows epileptic activity
- FHM2 mutant mice: Recapitulate migraine phenotype
- Humanized mice: Express human ATP1A2 variants
- Seizures and cortical spreading depression
- Reduced seizure threshold
- Impaired glutamate clearance
- Altered astrocyte morphology
Current research areas include:
- Structural studies: Cryo-EM structures of ATP1A2 to enable drug design
- Isoform-specific targeting: Developing drugs that selectively activate ATP1A2
- Gene therapy: AAV-mediated delivery to astrocytes
- Biomarker development: Identifying patients who might benefit from ATP1A2-targeted therapy
- Combination therapies: Targeting ATP1A2 with other disease mechanisms
- Astrocyte-specific approaches: Delivering therapy specifically to astrocytes
The ATP1A2 gene encodes the alpha-2 subunit of the Na⁺/K⁺-ATPase, a critical enzyme for astrocyte function and neuronal homeostasis. Its high expression in astrocytes makes it essential for potassium buffering, glutamate clearance, calcium signaling, and metabolic support of neurons. ATP1A2 mutations cause familial hemiplegic migraine and epilepsy, while reduced function contributes to ALS, AD, and PD pathogenesis. The dual role of ATP1A2 in both ion transport and cell signaling makes it a unique therapeutic target for neurodegenerative diseases. Understanding and manipulating ATP1A2 function offers potential for developing disease-modifying treatments that address astrocyte-neuron interactions central to neurodegeneration.